Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

Silverman, Stuart L.; Chines, Arkadi; Kendler, David L.; Kung, Annie W. C.; Teglbjærg, Christence Stubbe; Felsenberg, Dieter; Mairon, N.; Constantine, Ginger D.; Adachi, Jonathan D.

doi:10.1007/s00198-011-1691-1

Cited by 143 publications

(79 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It appears that this SERM does not stimulate but rather antagonizes endometrial growth in postmenopausal women (Ronkin et al, 2005). Other clinical trials revealed that bazedoxifene treatment prevents bone loss and reduces bone turnover with similar efficacy to raloxifene in postmenopausal women who have normal-to-low BMD without increasing mammographic breast density, the incidence of hot flashes Silverman et al, 2008Silverman et al, , 2012Archer et al, 2009;Harvey et al, 2009;Kanis et al, 2009;Pinkerton et al, 2009a;Christiansen et al, 2010;Bachmann et al, 2011;de Villiers et al, 2011;Xu et al, 2011). Bazedoxifene also displays efficacy for treating vasomotor symptoms and preventing endometrial hyperplasia in postmenopausal women Pinkerton et al, 2009b).…”

Section: Nuclear Receptors and Their Selective Modulatorsmentioning

confidence: 99%

Nuclear Receptors and Their Selective Pharmacologic Modulators

et al. 2013

View full text Add to dashboard Cite

Section: Nuclear Receptors and Their Selective Modulatorsmentioning

confidence: 99%

Nuclear Receptors and Their Selective Pharmacologic Modulators

et al. 2013

View full text Add to dashboard Cite

“…2 Bazedoxifene is not approved as a single agent ingredient; however, there are studies supporting its potential use as monotherapy in the prevention and treatment of osteoporosis in postmenopausal women. [3][4][5][6][7][8][9][10][11][12][13][14][15] Raloxifene, another SERM, is approved 1 Clinical effects observed in animal models include prevention of ovariectomy-associated body weight increases, 17 protection against ovariectomyassociated bone loss, [18][19][20] increased bone mineral density, 21,22 and increased bone compressive strength.…”

Section: Indicationsmentioning

confidence: 99%

Conjugated Estrogens and Bazedoxifene

Cada

Baker

2014

Hosp Pharm

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The March 2014 monograph topics are umeclidinium and vilanterol inhalation powder, sucroferric oxyhydroxide, luliconazole, edoxaban, and secukinumab. The DUE/MUE is on fentanyl transdermal system.

show abstract

“…The incidence of pulmonary or retinal vein thrombosis was similar among groups. None of these studies 48,51 showed a higher incidence of adverse effects on the cardiovascular system with bazedoxifene, including myocardial infarction and stroke. Also there seems to be a favorable effect (or at least without adverse significant effect) on the lipid profile.…”

Section: -50mentioning

confidence: 99%

Safety, Efficacy and Patient Acceptability of Bazedoxifene Acetate in the Management of Postmenopausal Osteoporosis

Fighera

Kulak

2012

Clin Med�Insights�Womens�Health

View full text Add to dashboard Cite

Many pharmacological agents are available for treatment of postmenopausal osteoporosis, including estrogen and the selective modulators of estrogen receptor (SERMS). Bazedoxifene is a third-generation SERM, which acts as estrogen agonist in bone and lipid metabolism and as an antagonist in the breast and endometrium. Studies demonstrated that bazedoxifene reduced significantly the risk of vertebral fractures. In a subgroup of patients at high risk (post-hoc analysis), a reduction of nonvertebral fractures risk was reported. Moreover, the combination of conjugated estrogens with bazedoxifene seems to offer an alternative to classical hormone therapy, improving the vasomotor symptoms and vaginal atrophy, without the use of a progestin. Bazedoxifene is a promising drug for the treatment and prevention of osteoporosis in postmenopausal women; however a safety concern regarding venous thromboembolic events is needed before starting treatment.

show abstract

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

Abstract: The findings support a sustained anti-fracture effect of bazedoxifene on new vertebral fractures in postmenopausal osteoporotic women and on non-vertebral fractures in the higher-risk subgroup of women.

Cited by 143 publications

References 35 publications

Nuclear Receptors and Their Selective Pharmacologic Modulators

Nuclear Receptors and Their Selective Pharmacologic Modulators

Conjugated Estrogens and Bazedoxifene

Safety, Efficacy and Patient Acceptability of Bazedoxifene Acetate in the Management of Postmenopausal Osteoporosis

Contact Info

Product

Resources

About